Cardiomagnum tablets p/o 75mg cont.

Name:
Cardiomagnum tablets p/o 75mg in a box. pack No. 10×3
Description:
tablets are white, round, biconvex, smooth on both sides. The main active ingredient Acetylsalicylic acid Form of release tablets coated Dosage 75 mg Indications for use Unstable angina pectoris – as part of standard therapy. Acute myocardial infarction – as part of standard therapy. Prevention of recurrent myocardial infarction. Prevention of recurrent transient ischemic attack (TIA) and recurrent cerebral infarction. Prevention of thrombosis after surgery and invasive interventions on the vessels (for example, after coronary artery bypass grafting (CABG) or primary percutaneous coronary intervention (PCI)). Prevention of cardiovascular disease in patients at high risk is possible only on prescription, if the benefits of therapy outweigh the risk of adverse events, in particular bleeding, and it is possible to diagnose occult bleeding. Note: Acetylsalicylic acid in a single dose of 75-150 mg is not intended for the treatment of pain. Dosage and administration Unstable angina pectoris: 75-150 mg 1 time per day. Acute myocardial infarction: 75-150 mg once a day. Prevention of recurrent myocardial infarction: 300 mg 1 time per day. Prevention of recurrent transient ischemic attack (TIA) and recurrent cerebral infarction: 75-150 mg 1 time per day. Prevention of thrombosis after surgery and invasive interventions on the vessels (for example, after coronary artery bypass grafting (CABG) or primary percutaneous coronary intervention (PCCI)): 75-150 mg 1 time per day. Antiplatelet therapy with acetylsalicylic acid is recommended to start 24 hours after CABG or PPCI. Prevention of cardiovascular diseases in patients at high risk (possible only on prescription, if the benefit of therapy outweighs the risk of adverse events): 75 mg 1 time per day. Method of application: Acetylsalicylic acid is recommended to be taken once a day, before meals, with plenty of liquid. In acute myocardial infarction, it is recommended to chew the first tablet and drink plenty of water. Acetylsalicylic acid 75 mg (100 mg) (150 mg) is intended for long-term use. The duration of therapy is determined by the doctor. Use in pregnancy and lactation Pregnancy Low doses (up to 100 mg/day) Clinical studies show that doses up to 100 mg/day are safe for use under certain conditions in pregnant women requiring some monitoring. Doses of 100-500 mg/day Insufficient clinical experience with doses of 100-500 mg/day requires following recommendations for doses of 500 mg/day or higher. Dose of 500 mg/day or higher First and second trimester: Prostaglandin synthesis inhibitors should only be given when absolutely necessary. The dose should be low and the time of application should be minimal. The appointment of salicylates during the third trimester of pregnancy is contraindicated, because. inhibitors of prostaglandin synthesis can lead to the following conditions in the fetus: cardiac toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); impaired kidney function, which can lead to kidney failure and, consequently, a decrease in the amount of amniotic fluid. At the end of pregnancy, the use of prostaglandin synthesis inhibitors can lead to: prolonged bleeding in the mother and fetus due to a decrease in platelet aggregation, which can occur even at low doses of the drug. to inhibition of uterine contraction, which can lead to a delay and duration of labor. Fertility: Acetylsalicylic acid is not recommended for women planning a pregnancy, because. inhibition of prostaglandin synthesis reduces fertility. The effect on fertility is reversible. If aspirin treatment is unavoidable, it should be as short as possible and at low doses. Suppression of prostaglandin synthesis can adversely affect pregnancy and / or intrauterine development of the embryo. Data from epidemiological studies show an increased risk of spontaneous abortion and congenital heart defects of the child and gasroschisis after the use of prostaglandin synthesis inhibitors in early pregnancy. The absolute risk of congenital heart disease increases from less than 1% to 1.5%, which is presumably associated with an increase in the dose and duration of treatment. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in losses before and after embryo implantation, and an increase in the incidence of malformations, incl. of cardio-vascular system. In view of the foregoing, the appointment of acetylsalicylic acid at a dose of 100 mg / day or higher is contraindicated in the third trimester of pregnancy. Breastfeeding Experience is limited. Before prescribing acetylsalicylic acid, the benefits of treatment should be assessed, taking into account the potential risk to the child. Precautions Take Cardiomagnum after a doctor’s prescription. Acetylsalicylic acid can provoke bronchospasm, as well as cause asthma attacks and other hypersensitivity reactions. Risk factors are the presence of a history of bronchial asthma, hay fever, nasal polyposis, chronic diseases of the respiratory system, as well as allergic reactions to other drugs (skin rash, itching, urticaria). Acetylsalicylic acid can cause bleeding of varying severity during and after surgery. The combination of acetylsalicylic acid with anticoagulants, thrombolytics and antiplatelet drugs is accompanied by an increased risk of bleeding. Acetylsalicylic acid in low doses can provoke the development of gout in predisposed individuals (having reduced excretion of uric acid). The combination of acetylsalicylic acid with methotrexate is accompanied by an increased incidence of side effects from the hematopoietic organs. Taking acetylsalicylic acid in high doses has a hypoglycemic effect, which must be borne in mind when prescribing it to patients with diabetes mellitus receiving hypoglycemic agents. With the combined appointment of glucocorticosteroids (GCS) and salicylates, it should be remembered that during treatment, the level of salicylates in the blood is reduced, and after the abolition of GCS, an overdose of salicylates is possible. The combination of acetylsalicylic acid with ibuprofen is not recommended, since the latter worsens the beneficial effect of acetylsalicylic acid on life expectancy. Exceeding the dose of acetylsalicylic acid is associated with a risk of gastrointestinal bleeding. Overdose is especially dangerous in elderly patients. When acetylsalicylic acid is combined with alcohol, the risk of damage to the gastrointestinal mucosa and prolongation of bleeding time is increased. Interaction with other drugs When used simultaneously, acetylsalicylic acid enhances the effect of the following drugs: methotrexate (by reducing renal clearance and displacing it from its association with proteins); heparin and indirect anticoagulants (due to impaired platelet function and displacement of indirect anticoagulants from their association with proteins); thrombolytic and antiplatelet drugs (ticlopidine), digoxin (due to a decrease in its renal excretion); hypoglycemic agents: insulin and sulfonylurea derivatives (due to the hypoglycemic properties of acetylsalicylic acid itself in high doses and the displacement of sulfonylurea derivatives from association with proteins); valproic acid (by displacing it from its association with proteins). An additive effect is observed while taking acetylsalicylic acid with ethanol (alcohol). Acetylsalicylic acid weakens the effect of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid. By enhancing the elimination of salicylates, systemic glucocorticosteroids weaken their effect. Antacids and cholestyramine, when used simultaneously, reduce the absorption of Cardiomagnum. Composition 1 tablet contains: active ingredient – acetylsalicylic acid – 75 mg, excipients: corn starch, microcrystalline cellulose, magnesium hydroxide, magnesium stearate; shell Aquarius Prefered HSP BPP218011 white: hypromellose, copovidone, polyethylene glycol, glycerylcaprylcaprate, polydextrose, titanium dioxide (E171). Overdose Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion. Treatment: dose reduction of the drug. Symptoms of severe overdose: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia. Treatment: immediate hospitalization in specialized departments for emergency therapy – gastric lavage, determination of acid-base balance, alkaline and forced alkaline diuresis, hemodialysis, administration of saline solutions, activated charcoal, symptomatic therapy. When performing alkaline diuresis, a pH value between 7.5 and 8 should be achieved. Forced alkaline diuresis should be performed when the plasma salicylate concentration is more than 500 mg/l (3.6 mmol/l) in adults and 300 mg/l (2.2 mmol/l) in children. Side effects The frequency of adverse reactions listed below was determined according to the following: very often -? 1/10; often -> 1/100, <1/10; sometimes -> 1/1000, <1/100; rarely -> 1/10,000, <1/1000; very rarely - <1/10,000, including individual messages. Allergic reactions: often - urticaria, angioedema. Immune system: sometimes - anaphylactic reactions. Gastrointestinal tract: very often - heartburn; often - nausea, vomiting; sometimes - pain in the abdomen, ulcers of the mucous membrane of the stomach and duodenum, incl. perforative (rarely), gastrointestinal bleeding; rarely - increased activity of liver enzymes, very rarely - stomatitis, esophagitis, toxic manifestations in the lower gastrointestinal tract with ulceration, strictures, colitis, exacerbation of intestinal irritation. Respiratory system: often - bronchospasm. Hematopoietic system: very often - increased bleeding; rarely - anemia; very rarely - hypoprothrombinemia, thrombocytopenia, neutropenia, aplastic anemia, eosinophilia, agranulocytosis. Central nervous system: sometimes - dizziness, drowsiness; often - headache, insomnia; rarely - tinnitus, intracerebral hemorrhage. Storage conditionsStore in a place protected from moisture and light at a temperature not exceeding 25°C. Keep out of the reach of children. Buy Cardiomagnum tablets p/o 75mg cont. cell.pack No. 15x2